Cardiac effects of magnesium sulfate pretreatment on acute dichlorvos-induced organophosphate poisoning: an experimental study in rats.
Although atropine and oximes are traditionally used in the management of organophosphate poisoning, investigations have been directed to finding additional therapeutic approaches. Thus, the aim of this study was to evaluate the cardiac effects of magnesium sulfate pretreatment on dichlorvos intoxication in rats. Rats were randomly divided into three groups as control, dichlorvos, and magnesium sulfate groups. After 6 h of dichlorvos or corn oil (as a vehicle) injection, venous blood samples were collected, and cardiac tissue samples were obtained. Biochemical analyses were performed to measure some parameters on serum and cardiac tissue. Immunohistochemical analyses of apoptosis and inducible nitric oxide (NO) synthase showed no change in cardiac tissue. Serum cholinesterase levels were markedly depressed with dichlorvos, and further suppressed markedly with magnesium sulfate pretreatment. Although we have demonstrated that serum NO levels in dichlorvos and magnesium sulfate groups were lower than the control group, cardiac tissue NO levels in magnesium sulfate group were higher than the other two groups. Mortality was not significantly affected with magnesium sulfate pretreatment. Uncertainty still persists on the right strategies for the treatment of organophosphate acute poisoning; however, it was concluded that our results do not suggest that magnesium sulfate therapy is beneficial in the management of acute dichlorvos-induced organophosphate poisoning, and also further studies are required.
Gunay
Nurullah
N
Department of Emergency Medicine, Kayseri Training and Research Hospital, Kayseri, Turkey. ngemergency@yahoo.com
Kekec
Zeynep
Z
Demiryurek
Seniz
S
Kose
Ataman
A
Namiduru
Emine S
ES
Gunay
Nahide E
NE
Sari
Ibrahim
I
Demiryurek
Abdullah T
AT
D000110:Acetylcholinesterase / Q000378:metabolism; D000818:Animals; D017209:Apoptosis / Q000502:physiology; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D002800:Cholinesterase Inhibitors / Q000506:poisoning*; D004006:Dichlorvos / Q000506:poisoning*; D005978:Glutathione / Q000378:metabolism; D006321:Heart / Q000187:drug effects*; D006801:Humans; D008278:Magnesium Sulfate / Q000494:pharmacology*; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D015996:Survival Rate
D002121:Calcium Channel Blockers; D002800:Cholinesterase Inhibitors; D009569:Nitric Oxide; D008315:Malondialdehyde; D008278:Magnesium Sulfate; D004006:Dichlorvos; D052247:Nitric Oxide Synthase Type II; D000110:Acetylcholinesterase; D005978:Glutathione